Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review
Young KG., McInnes EH., Massey RJ., Kahkoska AR., Pilla SJ., Raghavan S., Stanislawski MA., Tobias DK., McGovern AP., Dawed AY., Jones AG., Pearson ER., Dennis JM., Tobias DK., Merino J., Ahmad A., Aiken C., Benham JL., Bodhini D., Clark AL., Colclough K., Corcoy R., Cromer SJ., Duan D., Felton JL., Francis EC., Gillard P., Gingras V., Gaillard R., Haider E., Hughes A., Ikle JM., Jacobsen LM., Kettunen JLT., Kreienkamp RJ., Lim L-L., Männistö JME., Massey R., Mclennan N-M., Miller RG., Morieri ML., Most J., Naylor RN., Ozkan B., Patel KA., Pilla SJ., Prystupa K., Raghaven S., Rooney MR., Schön M., Semnani-Azad Z., Sevilla-Gonzalez M., Svalastoga P., Takele WW., Tam CH-T., Thuesen ACB., Tosur M., Wallace AS., Wang CC., Wong JJ., Yamamoto JM., Young K., Amouyal C., Andersen MK., Bonham MP., Chen M., Cheng F., Chikowore T., Chivers SC., Clemmensen C., Dabelea D., Dawed AY., Deutsch AJ., Dickens LT., DiMeglio LA., Dudenhöffer-Pfeifer M., Evans-Molina C., Fernández-Balsells MM., Fitipaldi H., Fitzpatrick SL., Gitelman SE., Goodarzi MO., Grieger JA., Guasch-Ferré M., Habibi N., Hansen T., Huang C., Harris-Kawano A., Ismail HM., Hoag B., Johnson RK., Jones AG., Koivula RW., Leong A., Leung GKW., Libman IM., Liu K., Long SA., Lowe WL., Morton RW., Motala AA., Onengut-Gumuscu S., Pankow JS., Pathirana M., Pazmino S., Perez D., Petrie JR., Powe CE., Quinteros A., Jain R., Ray D., Ried-Larsen M., Saeed Z., Santhakumar V., Kanbour S., Sarkar S., Monaco GSF., Scholtens DM., Selvin E., Sheu WH-H., Speake C., Stanislawski MA., Steenackers N., Steck AK., Stefan N., Støy J., Taylor R., Tye SC., Ukke GG., Urazbayeva M., Van der Schueren B., Vatier C., Wentworth JM., Hannah W., White SL., Yu G., Zhang Y., Zhou SJ., Beltrand J., Polak M., Aukrust I., de Franco E., Flanagan SE., Maloney KA., McGovern A., Molnes J., Nakabuye M., Njølstad PR., Pomares-Millan H., Provenzano M., Saint-Martin C., Zhang C., Zhu Y., Auh S., de Souza R., Fawcett AJ., Gruber C., Mekonnen EG., Mixter E., Sherifali D., Eckel RH., Nolan JJ., Philipson LH., Brown RJ., Billings LK., Boyle K., Costacou T., Dennis JM., Florez JC., Gloyn AL., Gomez MF., Gottlieb PA., Greeley SAW., Griffin K., Hattersley AT., Hirsch IB., Hivert M-F., Hood KK., Josefson JL., Kwak SH., Laffel LM., Lim SS., Loos RJF., Ma RCW., Mathieu C., Mathioudakis N., Meigs JB., Misra S., Mohan V., Murphy R., Oram R., Owen KR., Ozanne SE., Pearson ER., Perng W., Pollin TI., Pop-Busui R., Pratley RE., Redman LM., Redondo MJ., Reynolds RM., Semple RK., Sherr JL., Sims EK., Sweeting A., Tuomi T., Udler MS., Vesco KK., Vilsbøll T., Wagner R., Rich SS., Franks PW.
Abstract Background A precision medicine approach in type 2 diabetes requires the identification of clinical and biological features that are reproducibly associated with differences in clinical outcomes with specific anti-hyperglycaemic therapies. Robust evidence of such treatment effect heterogeneity could support more individualized clinical decisions on optimal type 2 diabetes therapy. Methods We performed a pre-registered systematic review of meta-analysis studies, randomized control trials, and observational studies evaluating clinical and biological features associated with heterogenous treatment effects for SGLT2-inhibitor and GLP1-receptor agonist therapies, considering glycaemic, cardiovascular, and renal outcomes. After screening 5,686 studies, we included 101 studies of SGLT2-inhibitors and 75 studies of GLP1-receptor agonists in the final systematic review. Results Here we show that the majority of included papers have methodological limitations precluding robust assessment of treatment effect heterogeneity. For SGLT2-inhibitors, multiple observational studies suggest lower renal function as a predictor of lesser glycaemic response, while markers of reduced insulin secretion predict lesser glycaemic response with GLP1-receptor agonists. For both therapies, multiple post-hoc analyses of randomized control trials (including trial meta-analysis) identify minimal clinically relevant treatment effect heterogeneity for cardiovascular and renal outcomes. Conclusions Current evidence on treatment effect heterogeneity for SGLT2-inhibitor and GLP1-receptor agonist therapies is limited, likely reflecting the methodological limitations of published studies. Robust and appropriately powered studies are required to understand type 2 diabetes treatment effect heterogeneity and evaluate the potential for precision medicine to inform future clinical care.